Summary
A child with subacute sclerosing panencephalitis (SSPE) received intraventricular alpha interferon (IFN) as experimental treatment. The course was monitored by colleagues in pediatric neurology, neuro-opthalmology and clinical psychology, also by monthly EEGS and brain CT scans. Two courses of IFN were administered. During the first course, improvement occurred nearly to the premorbid level of function. About 1 month after this trial was stopped, a severe recrudescence rapidly produced a thalamic state. A second trial of IFN resulted in less improvement. When the brain CT showed severe degeneration, the second trial was stopped. Intraventricular administration of alpha IFN was well tolerated in both courses of therapy. Alpha IFN has promise in the treatment of SSPE but the optimal dosage and duration of treatment are undetermined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Behan PO (1981) Interferon in the treatment of subacute sclerosing panencephalitis. Lancet I:1059–1060
Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR (1984) Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38:745–755
Graves MC (1984) Subacute sclerosing panencephalitis. Neurol Clin 2:267–280
Katz SL, Enders JF (1969) Measles virus. In: Lennette EH, Schmidt NJ (eds) Diagnostic procedures for viral and rickettsial infections, 4th edn. American Public Health Association, New York, pp 523–525
Panitch HS, Gomez-Plascencia J, Norris FH, Cantell K, Smith RA (1986) Remission of subacute sclerosing panencephalitis in patients treated with intraventricular interferon. Neurology (Cleveland) (in press)
Picchietti DL, Huttenlocher PR, Roos RP, Horowitz B, Wiebe ME (1983) Intrathecal interferon in subacute sclerosing panencephalitis (SSPE). Neurology (NY) [Suppl 2] 33:226
Resnick JS, Engel WK, Sever JL (1968) Subacute sclerosing panencephalitis: spontaneous improvement in a patient with elevated measles antibody in blood and spinal fluid. N Engl J Med 279:126–130
Risk WS, Haddad FS (1979) The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch Neurol 36:610–614
Salazar AM, Gibbs CJ, Gajdusek DC, Smith RA (1984) Clinical use of interferons: central nervous system disorders. In: Came PE, Carter WA (eds) Interferons and their applications. Springer, Berlin Heidelberg New York Tokyo, pp 472–497
Smith RA, Norris FH, Palmer D, Bernhardt L, Wills RJ (1985) Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 37:85–88
Tourtelotte WW, Ma BI, Brandes DB (1981) Quantification of de novo central nervous system IgG measles antibody synthesis in SSPE. Ann Neurol 9:551–556
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Norris, F.H., Panitch, H.S., Denys, E.H. et al. The treatment of subacute sclerosing panencephalitis with interferon: a case report. J Neurol 233, 102–107 (1986). https://doi.org/10.1007/BF00313855
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00313855